Sign up
Pharma Capital

Fiji Kava applauds government decision to ease kava import regulations

The easing on restrictions represents a growing acceptance of kava as a natural and safe alternative for managing stress and anxiety.
1547793909_FIJ-image-757.jpg
Kava is made from the root or stump of the kava shrub

Fiji Kava Ltd (ASX:FIJ) has had its efforts to make kava a new alternative to prescription medication validated by an Australian government easing kava importation regulations.

A significant breakthrough for the kava industry, the announcement represents a growing acceptance of Kava as a natural and safe alternative for managing stress and anxiety.

This move aligns with Fiji Kava’s efforts to make Kava a new alternative prescription medication, such as Valium and Xanax, currently representing a US$15 billion global benzodiazepine market.

Aligns with effort to make Kava alternative prescription

On a recent trip to Vanuatu last week Australian Prime Minister Scott Morrison announced the government will be working towards putting a pilot program in place “to ease some of the limitations on importation of kava into Australia.”

Morrison said: “Kava is an important product which is produced here and has a great and successful market around the world.”

“Step in the right direction”

Fiji Kava managing director Zane Yoshida said: “We are encouraged by the announcement made by Australian Prime Minister Scott Morrison.

“This is certainly a step in the right direction and Fiji Kava looks forward to the development of the pilot program.”

Cultural practice

Kava is a depressant drug that is traditionally consumed by Pacific Islanders in drink form for ceremonies and cultural practices.

According to the Australian Alcohol and Drug Foundation, many Pacific Islanders who have settled in Australia have continued drinking kava or using kava extracts.

Kava extracts are used in some herbal preparations and sold as over-the-counter tablets to treat insomnia, stress and anxiety.

- Jessica Cummins



Register here to be notified of future FIJ Company articles
View full FIJ profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.